iPSC Platform Target customers with drug discovery programs leveraging human iPSC-derived models and high-throughput screening. Ncardia’s expertise and ready-to-use assay panels position them as a one-stop solution for stem cell-based disease modeling and screening workflows.

Commercial Scale Explore opportunities for tiered collaboration and contract development manufacturing (CDMO) support through Cellistic, focusing on large-scale iPSC process development and manufacturing for allogeneic cell therapies.

Global Partnerships Prioritize outreach to biopharma companies worldwide seeking scalable stem cell platforms, with emphasis on cardiovascular disease models and hypertrophic cardiomyopathy platforms historically developed by Ncardia.

Digital Engagement Leverage Ncardia’s tech stack and digital presence to target prospects via inbound interest in iPSC models, ready-to-use assays, and niche platforms like Ncyte NHP-C cardiomyocytes for safety assessment and translational studies.

Leadership & Growth Align with executive hires and strategic partnerships to identify collaboration opportunities in co-development of iPSC-based solutions, including emerging cell therapies and precision medicine workflows.